Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine

J Infect. 2022 Jan;84(1):94-118. doi: 10.1016/j.jinf.2021.08.008. Epub 2021 Aug 8.
No abstract available

Keywords: Adverse events; Antibody response; BNT162b2 vaccine; Delayed second vaccine dose; Neutralizing antibody; RBD-binding IgG antibody; SARS-CoV-2 infection; mRNA vaccine.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibody Formation
  • BNT162 Vaccine*
  • COVID-19*
  • Humans
  • SARS-CoV-2
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • Vaccines, Synthetic
  • mRNA Vaccine
  • mRNA Vaccines
  • BNT162 Vaccine